Graviton

Graviton is a New York-based company founded in 2020 with the goal of developing novel therapeutics for the treatment of autoimmune, cancer, certain genetic, fibrotic and other serious diseases. TDI01, a highly selective, potent inhibitor of Rho/Rho associated coiled-coil containing protein kinase 2 (ROCK2) is currently being studied in the United States for the treatment of idiopathic pulmonary fibrosis (IPF).In February 2021, Graviton Bioscience Corporation and Beijing Tide Pharmaceutical Co., Ltd. announced the signing of an exclusive license agreement for TDI01